OSLO,
Norway, Nov. 23, 2022 /PRNewswire/ --
Navamedic has signed an agreement with its partner InfoRLife
SA (subsidiary of ACS Dobfar S.p.A.) which will expand Navamedic's
portfolio of antibiotics for hospital use. Under the agreement,
Navamedic acquires the rights and Marketing Authorizations for the
unique Clindamycin ready-to-administer bags developed and
manufactured by InfoRLife AS. Navamedic already markets Clindamycin
in traditional ampoules as part of the large portfolio of
antibiotics acquired from ACS Dobfar in 2020. The innovative
ready-to-use product will thus complement this
portfolio.
Clindamycin is a well-established antibiotic used in
treatment of severe infections, including staphylococcal bone and
joint infections, chronic sinusitis and infections of the lower
respiratory tract. The primary benefits of this ready-to-use
packaging are a reduction in medication errors, the reduced risk of
contamination, storage at ambient temperature, as well as nurse
time saving and a reduction of waste.
"With our efficient market access and strong local
competence we launch and strive to enhance the value of products
and brands, and this acquisition demonstrates how we continue to
build assets of owned products. Over the recent months we have made
a string of new product launches, partnerships and acquisitions,
all bringing us closer to our NOK 1
billion revenue target in the mid- to long-term," says
Kathrine Gamborg Andreassen, CEO of
Navamedic ASA.
The Clindamycin ready-to-administer bags have been on the
market in Norway, Sweden and Denmark since 2020 under the label of
Villerton (owned by ACS Dobfar), mainly being sold through national
and regional hospital tenders. The transfer of the marketing
authorizations will be initiated within short and the product is
expected to be on the market under the Navamedic label from early
2023.
For further information, please contact:
Kathrine Gamborg
Andreassen, CEO, Navamedic
Mobile: +47 951
78680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47
917 62842
E-mail:
lars.hjarrand@navamedic.com
About Navamedic ASA:
Navamedic ASA is a Nordic pharma company and reliable
provider of high-quality products, delivered to hospitals and
through pharmacies, meeting the specific needs of patients and
consumers by leveraging its highly scalable market access platform,
leading category competence and local knowledge. Navamedic is
present in all the Nordic countries, the Baltics and Benelux, with
sales representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA).
View original
content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-acquires-innovative-antibiotic-product-for-hospital-use-in-the-nordic-region-301686012.html